

Major bleeding reduced in patients having non-cardiac surgery

April 4 2022

The NEW ENGLAND JOURNAL of MEDICINE

RESEARCH SUMMARY High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality Devereaux PJ et al. DOI: 10.1056/NEJMoa2000803 Postoperative Cardiac Troponin I Level Measurements CLINICAL PROBLEM Consensus recommendations regarding the threshold levels of cardiac troponin elevations for identifying clinically important myocardial injury during or after cardiac surgery vary, from more than 10 times to 70 or more times the upper reference limit of the assay. Evidence underlying these recommendations is limited. 3-12 hours after Postoperative days cardiac surgery 1, 2, and 3 STUDY DESIGN An international, prospective cohort study examined Threshold Troponin Value, within 1 Day after Surgery, Associated with the relationship between high-sensitivity cardiac tro-Adjusted HR >1.00 for 30-Day Mortality ponin I after cardiac surgery and clinical outcomes 14,000 in 13,862 patients 18 years of age or older. Patients 12,981 ng/liter 13,500 underwent troponin I measurement (upper reference 2673 to 16,591 ng/liter 13,000 499x limit, 26 ng per liter) 3 to 12 hours after surgery and 12,500 on days 1, 2, and 3 after surgery. The primary out-12,000 come was death within 30 days after surgery. 11,500 11.000 10,500 RESULTS 10,000 By day 30 after surgery, 2.1% of the patients had died. 9500-

Credit: *New England Journal of Medicine* (2022). DOI: 10.1056/NEJMoa2000803

A large, international study found a drug that helps the blood to clot reduced life-threatening, major and critical organ bleeding in patients



undergoing non-cardiac surgery—without increasing major vascular complications.

The drug tested, tranexamic acid (TXA), was given to patients at risk of bleeding or vascular complications. The study found that TXA did not increase deep vein clotting known as VTE, <u>heart attack</u>, non-hemorrhagic stroke, or other major vascular complication in the 30 days after surgery.

In the study, half of 9,535 patients in 22 countries were randomly assigned TXA, half placebo. Patients were 45 years or older (average age 69 years); 44% of them were female.

The study was published today in the *New England Journal of Medicine*, and simultaneously presented at American College of Cardiology's ACC 2022 conference by senior author P.J. Devereaux.

"Bleeding is a common problem in patients undergoing noncardiac surgery and it often results in patients requiring a <u>blood transfusion</u>. Our study demonstrates that tranexamic acid can prevent this problem," said Devereaux, a senior scientist at the Population Health Research Institute of McMaster University and Hamilton Health Sciences (HHS).

"Additionally, our finding of a safe, effective reduction in surgical bleeding has the potential to help healthcare systems on a broader, trickle-down effect."

"Surgical bleeding accounts for 40% of all transfusions, and more blood products are needed than are available today around the world," added Devereaux, who is also a professor of medicine and of health research methods, evidence and impact at McMaster, and a cardiologist and perioperative care physician at HHS.



"Reduced bleeding that's safe for patients could address the challenge of insufficient blood supply and save more lives."

"In our trial, tranexamic acid demonstrated a consistent reduction in the risk of bleeding based on several definitions, and it reduced the risk of receiving 1 or 2 to 4 transfusions," says PHRI scientist and study co-author Maura Marcucci.

"Given that 300 million surgeries occur annually around the world, <u>tranexamic acid</u> has the potential for large public health and clinical benefits," added Marcucci. She is an assistant professor of medicine and of health research methods, evidence and impact at McMaster, and an internal medicine physician at HHS.

More information: P.J. Devereaux et al, High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality, *New England Journal of Medicine* (2022). DOI: 10.1056/NEJMoa2000803

Provided by McMaster University

Citation: Major bleeding reduced in patients having non-cardiac surgery (2022, April 4) retrieved 11 May 2024 from <u>https://medicalxpress.com/news/2022-04-major-patients-non-cardiac-surgery.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.